Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Immune checkpoint inhibitors (ICIs) targeting immune checkpoint proteins, such as CTLA-4 and PD-1/PD-L1, have demonstrated remarkable and durable clinical responses in various cancer types. However, a considerable number of patients receiving ICIs eventually experience a relapse due to diverse resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhou, Hsu, Jennifer L., Li, Yintao, Hortobagyi, Gabriel N., Hung, Mien-Chie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387712/
https://www.ncbi.nlm.nih.gov/pubmed/32775303
http://dx.doi.org/10.3389/fonc.2020.01197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387712/
https://www.ncbi.nlm.nih.gov/pubmed/32775303
http://dx.doi.org/10.3389/fonc.2020.01197

Ejemplares similares